What's the mechanism behind the low response (less sensitivity or resistance) of Lung cancer patients with EGFR or ALK mutation to checkpoint inhibitors (such as PD1 and PD-L1 inhibitors)?
Tomas Koltai
Not all lung cancers overexpress PD1 and PD-L1. That is the reason of a bad result. PD-L1 was only expressed in 43% of patients with NSCLC and patients may shift during their evolution. For more information please read:
Chen J, Li H, Pang RL, Huang J. Oncotargets and Therapy.2017;10:2003-2017
https://doi.org/10.2147/OTT.S127498
1 votes
1 thanks
- Badges
- Science topic
More Abdulqadir J. Nashwan's questions See All
Similar questions and discussions